293 related articles for article (PubMed ID: 26679378)
1. Prediction of vascular invasion in hepatocellular carcinoma by next-generation des-r-carboxy prothrombin.
Kurokawa T; Yamazaki S; Mitsuka Y; Moriguchi M; Sugitani M; Takayama T
Br J Cancer; 2016 Jan; 114(1):53-8. PubMed ID: 26679378
[TBL] [Abstract][Full Text] [Related]
2. Next-generation des-r-carboxy prothrombin for immunohistochemical assessment of vascular invasion by hepatocellular carcinoma.
Yamazaki S; Takayama T; Kurokawa T; Shimamoto N; Mitsuka Y; Yoshida N; Higaki T; Sugitani M
BMC Surg; 2020 Sep; 20(1):201. PubMed ID: 32928172
[TBL] [Abstract][Full Text] [Related]
3. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of alpha-fetoprotein and des-gamma-carboxyprothrombin in nigerians with hepatocellular carcinoma.
Ette AI; Ndububa DA; Adekanle O; Ekrikpo U
Niger J Clin Pract; 2017 Oct; 20(10):1267-1272. PubMed ID: 29192630
[TBL] [Abstract][Full Text] [Related]
5. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
[TBL] [Abstract][Full Text] [Related]
6. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
7. A combination of α-fetoprotein and des-γ-carboxy prothrombin is superior in detection of hepatocellular carcinoma.
Ertle JM; Heider D; Wichert M; Keller B; Kueper R; Hilgard P; Gerken G; Schlaak JF
Digestion; 2013; 87(2):121-31. PubMed ID: 23406785
[TBL] [Abstract][Full Text] [Related]
8. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
[TBL] [Abstract][Full Text] [Related]
9. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
[TBL] [Abstract][Full Text] [Related]
10. Des-γ-carboxy prothrombin ratio measured by P-11 and P-16 antibodies is a novel biomarker for hepatocellular carcinoma.
Tameda M; Shiraki K; Sugimoto K; Ogura S; Inagaki Y; Yamamoto N; Ikejiri M; Takei Y; Ito M; Nobori T
Cancer Sci; 2013 Jun; 104(6):725-31. PubMed ID: 23480217
[TBL] [Abstract][Full Text] [Related]
11. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
[TBL] [Abstract][Full Text] [Related]
12. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic accuracy of des-gamma-carboxy prothrombin for hepatocellular carcinoma in a French cohort using the Lumipulse
Sultanik P; Ginguay A; Vandame J; Popovici T; Meritet JF; Cynober L; Pol S; Bories PN
J Viral Hepat; 2017 Jan; 24(1):80-85. PubMed ID: 27699936
[TBL] [Abstract][Full Text] [Related]
14. Clinical significance of simultaneous determinations of alpha-fetoprotein and des-gamma-carboxy prothrombin in monitoring recurrence in patients with hepatocellular carcinoma.
Aoyagi Y; Oguro M; Yanagi M; Mita Y; Suda T; Suzuki Y; Hata K; Ichii K; Asakura H
Cancer; 1996 May; 77(9):1781-6. PubMed ID: 8646674
[TBL] [Abstract][Full Text] [Related]
15. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
[TBL] [Abstract][Full Text] [Related]
16. New scoring system for prediction of microvascular invasion in patients with hepatocellular carcinoma.
Shirabe K; Toshima T; Kimura K; Yamashita Y; Ikeda T; Ikegami T; Yoshizumi T; Abe K; Aishima S; Maehara Y
Liver Int; 2014 Jul; 34(6):937-41. PubMed ID: 24393295
[TBL] [Abstract][Full Text] [Related]
17. Determination of optimum cutoff levels of plasma des-gamma-carboxy prothrombin and serum alpha-fetoprotein for the diagnosis of hepatocellular carcinoma using receiver operating characteristic curves.
Fujiyama S; Izuno K; Yamasaki K; Sato T; Taketa K
Tumour Biol; 1992; 13(5-6):316-23. PubMed ID: 1283927
[TBL] [Abstract][Full Text] [Related]
18. Clinical utility of simultaneous measurement of alpha-fetoprotein and des-γ-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: A multi-center case-controlled study of 1,153 subjects.
Song P; Feng X; Inagaki Y; Song T; Zhang K; Wang Z; Zheng S; Ma K; Li Q; Kong D; Wu Q; Zhang T; Zhao X; Hasegawa K; Sugawara Y; Kokudo N; Tang W;
Biosci Trends; 2014 Oct; 8(5):266-73. PubMed ID: 25382443
[TBL] [Abstract][Full Text] [Related]
19. Des-gamma-carboxy prothrombin and alpha-fetoprotein positive status as a new prognostic indicator after hepatic resection for hepatocellular carcinoma.
Shimada M; Takenaka K; Fujiwara Y; Gion T; Kajiyama K; Maeda T; Shirabe K; Sugimachi K
Cancer; 1996 Nov; 78(10):2094-100. PubMed ID: 8918402
[TBL] [Abstract][Full Text] [Related]
20. Comparison of clinicopathological features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein alone and those seropositive for des-gamma-carboxy prothrombin alone.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
J Gastroenterol Hepatol; 2001 Nov; 16(11):1290-6. PubMed ID: 11903749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
